About this event
Thursday 16th, 23rd & 30th July 2026 at 3pm BST | 4pm CEST | 10am EST
Liquid biopsy is rapidly transforming how cancer is detected, monitored, and treated. While major progress has been made in identifying tumour-derived signals in blood, the central challenge now is translating these advances into robust, clinically deployable tools that improve patient outcomes.
This three-part webinar series moves beyond the hype to focus on what it takes to bring liquid biopsy into routine clinical practice. Across the series, we will explore how assays are engineered to detect rare tumour signals, how emerging biomarker strategies are reshaping performance, and how these technologies are being validated and implemented in clinical trials and healthcare systems.
Thursday 16th July 2026 | 3pm BST | 4pm CEST | 10am EST
Sponsored by Twist Bioscience
As liquid biopsy applications expand into earlier cancer detection and increasingly challenging clinical settings, assay performance has never been more critical. This session will explore how researchers and technology developers are improving assay sensitivity through advances in sequencing strategies, target enrichment and workflow optimisation. It will also examine how assay design decisions impact reproducibility, scalability and suitability for downstream use in translational research and clinical studies.
Key Takeaways
Talk 1: Implementing Liquid Biopsy in Paediatric Oncology: Balancing Breadth, Cost, and Clinical Utility
Alexandre Rouette, Clinical Specialist, CHU Sainte-Justine Children's Hospital
Talk 2: Customizable Genomic Profiling of Cell-Free DNA for Oncology
James Flynn, Senior Staff Product Manager, Twist Bioscience
Talk 3: Evaluating Whole Blood as an Alternative to Plasma for Liquid Biopsy Applications
Maria Neofytou, Lecturer, University of Westminster
Thursday 23rd July 2026 at 3pm BST/ 4pm CEST/ 10am EST
Sponsored by Thermo Fisher Scientific
This webinar will bring together academic, clinical and industry perspectives to examine whether next-generation liquid biopsy approaches are truly delivering on their promise. As new biomarker strategies such as fragmentomics, methylation and multi-modal assays rapidly emerge, which approaches are showing the greatest clinical value—and which still require further validation?
Through real-world case studies and expert discussion, attendees will gain practical insight into the strengths, limitations and trade-offs of different biomarker strategies, including sensitivity, specificity, scalability and clinical utility, and what these advances could mean for the future of cancer detection and patient management.
Key Takeaways
Talk 1: Rethinking Liquid Biopsy: From Targeted Panels to Multimodal Detection
Ariane Hallermayr, Head of Research and Development, Medical Genetics Centre
Talk 2: Expanding the Role of CTCs and Immune Cells in Cancer Detection and Monitoring
Catherine Alix-Panabières, Professor of Oncology and Director of the Laboratory of Rare Human Circulating Cells, University of Montpellier
Talk 3: Enhancing Signal Detection in Multi-Omic Spatial Analysis for Early Cancer Insights
Dineika Chandrananda, Senior Bioinformatics Research Officer, Peter MacCallum Cancer Centre
Thursday 30th July 2026 at 3pm BST/ 4pm CEST/ 10am EST
To realise the full potential of liquid biopsy, these technologies must be successfully integrated into clinical trials and healthcare systems. This requires evidence of clinical utility, clear regulatory pathways and practical strategies for implementation at scale.
This interactive panel will bring together experts from academia, healthcare and industry to discuss what it will take for liquid biopsy to move beyond promising research and become part of routine cancer care. Panellists will explore how liquid biopsy assays are informing clinical trial design, what evidence is needed to demonstrate clinical utility, and the practical challenges of implementing these technologies at scale.
Through a moderated discussion, the panel will debate whether current evidence is sufficient for wider adoption, examine lessons from multi-cancer early detection and other clinical studies, and consider how emerging approaches, including multi-modal liquid biopsy, could shape the future of precision oncology.
Key Takeaways:
Panellists:
Daniel Stetson, Director of Translational Genomics, AstraZeneca
Magda Meissner, Clinical Liquid Biopsy Lead, All Wales Medical Genomics Services
Florent Mouliere, Team Lead, National Biomarker Centre, CRUK Manchester Institute
Hosted by
Front Line Genomics is a genomics-focused social business, with a mission to deliver the benefits of genomics to patients faster. We organize the Festival of Genomics & Biodata, webinars, reports and smaller boardroom-style strategy meetings.